NDA 210361 · Journey
Qbrexza
Glycopyrronium Tosylate · Topical
Last checked: Nov 20, 2026Latest source record: Oct 28, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Jun 28, 2018
Approved uses
1
Original approval plus efficacy supplements
Registered trials
160
72 Phase 3, 12 recruiting
FAERS reports
1,551
788 serious, 99 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 21, 2026.
Qbrexza is indicated for topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older. Qbrexza is an anticholinergic indicated for topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older ( 1 ).
Mechanism: Glycopyrronium is a competitive inhibitor of acetylcholine receptors that are located on certain peripheral tissues, including sweat glands. In hyperhidrosis, glycopyrronium inhibits the action of acetylcholine on sweat glands, reducing sweating.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- QBREXZA · GLYCOPYRRONIUM TOSYLATE EQ 2.4% BASE · CLOTH, TOPICAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Glycopyrronium" as an intervention, any sponsor and status, largest first.
- Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)Pivotal-lookingCompleted
Pearl Therapeutics, Inc.Industry
NCT02465567 · 8,588 participants · Start Jun 30, 2015 · Primary completion Jul 26, 2019
Drug: BGF MDI 320/14.4/9.6 μg; GFF MDI 14.4/9.6 μg and 2 more · For: COPD
Sites: Andalusia, Alabama; Athens, Alabama; Birmingham, Alabama · 741 sites in all
- A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseasePivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06283966 · 5,250 participants (planned) · Start Feb 21, 2024 · Primary completion Dec 3, 2027
Drug: BGF MDI 320/14.4/9.6 μg; GFF MDI 14.4/9.6 μg · For: COPD (Chronic Obstructive Pulmonary Disease)
Sites: Athens, Alabama; Cullman, Alabama; Fairhope, Alabama · 922 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT01985334 · 4,389 participants · Start Feb 14, 2014 · Primary completion Apr 29, 2016
Drug: Glycopyrronium; SABA and 5 more · For: COPD
Sites: Amstetten, Austria; Feldkirch, Austria; Hallein, Austria · 542 sites in all
- A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPDPivotal-lookingCompleted
Chiesi Farmaceutici S.p.A.Industry
NCT04320342 · 3,406 participants · Start Apr 27, 2022 · Primary completion Jan 12, 2026
Drug: Beclomethasone Dipropionate; Glycopyrronium Bromide and 1 more · For: COPD; COPD Exacerbation
Sites: Birmingham, Alabama; Dothan, Alabama; Foley, Alabama · 436 sites in all
- QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01782326 · 3,362 participants · Start Jul 2013 · Primary completion Sep 2015
Drug: QVA149; Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS) · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Ciudad de Buenos Aires, Argentina; Buenos Aires, Argentina; Caba, Argentina · 499 sites in all
- Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With AsthmaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02571777 · 3,092 participants · Start Dec 8, 2015 · Primary completion Jun 14, 2019
Drug: QVM149 150/50/160; QVM149 150/50/80 and 3 more · For: Asthma
Sites: Bahía Blanca, Argentina; CABA, Argentina; Florida, Argentina · 403 sites in all
- Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT04609878 · 2,274 participants · Start Dec 15, 2020 · Primary completion Mar 21, 2025
Drug: BGF MDI 320/28.8/9.6 μg; BGF MDI 320/14.4/9.6 μg and 2 more · For: Asthma
Sites: Saraland, Alabama; Phoenix, Arizona; Sun City West, Arizona · 360 sites in all
- Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) ExacerbationsPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01120691 · 2,224 participants · Start Apr 2010 · Primary completion Jul 2012
Drug: QVA149; NVA237 and 2 more · For: Chronic Obstructive Pulmonary Disease
Sites: Birmingham, Alabama; Fairhope, Alabama; Florence, Alabama · 342 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- mydriasis273
- dry mouth241
- off label use195
- vision blurred188
- drug ineffective97
- intentional product misuse94
- urinary retention89
- headache85
- constipation72
- dyspnoea69
- pneumonia59
- nausea54
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 3 |
| 2009 | 3 |
| 2010 | 3 |
| 2011 | 2 |
| 2012 | 5 |
| 2013 | 6 |
| 2014 | 8 |
| 2015 | 17 |
| 2016 | 37 |
| 2017 | 39 |
| 2018 | 57 |
| 2019 | 491 |
| 2020 | 226 |
| 2021 | 170 |
| 2022 | 89 |
| 2023 | 106 |
| 2024 | 121 |
| 2025 | 103 |
| 2026 | 65 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Qbrexza (Glycopyrronium Tosylate)
2024 spending
$2.0M
Beneficiaries
947
2,848 claims
Per beneficiary
$2,159
$21.13 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $939,657 |
| 2023 | $1,842,539 |
| 2024 | $2,044,939 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials.
Papi A, Wise RA, Jackson DJ, et al. · Lancet Respir Med 2026 · Multicenter Study, Randomized Controlled Trial
- Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.
Wedzicha JA, Banerji D, Chapman KR, et al. · N Engl J Med 2016 · Comparative Study, Multicenter Study
- Organophosphorus poisoning (acute).
Eddleston M, Singh S, Buckley N · BMJ Clin Evid 2007 · Systematic Review
- Organophosphorus poisoning (acute).
Blain PG · BMJ Clin Evid 2011 · Systematic Review
- Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.
Ismaila AS, Haeussler K, Czira A, et al. · Adv Ther 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies for Patients with COPD and Phenotypic Features of Asthma: A Pooled Post Hoc Analysis of KRONOS and ETHOS.
Muro S, Seki M, Hurst JR, et al. · Int J Chron Obstruct Pulmon Dis 2024 · Clinical Trial, Phase III, Comparative Study
Sponsor: Journey
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.